title: Raltegravir. In HIV-infected in children at least 2 years of age. Only after prior treatment failure.
abstract: The first integrase inhibitor to be approved for children; antiretroviral effect similar to that observed in adults in treatment failure; no first-line evaluation.
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D013607:Tablets; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D013607:Tablets; D000068898:Raltegravir Potassium